ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100. A total of 22 filers reported holding ALPINE IMMUNE SCIENCES INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $127,410 | +409.6% | 12,394 | +105.1% | 0.00% | – |
| Q2 2019 | $25,000 | -41.9% | 6,042 | -4.1% | 0.00% | – |
| Q1 2019 | $43,000 | +72.0% | 6,303 | -6.5% | 0.00% | – |
| Q4 2018 | $25,000 | -41.9% | 6,741 | -1.8% | 0.00% | – |
| Q3 2018 | $43,000 | -38.6% | 6,868 | -25.9% | 0.00% | – |
| Q2 2018 | $70,000 | +11.1% | 9,263 | +17.8% | 0.00% | – |
| Q1 2018 | $63,000 | -28.4% | 7,863 | 0.0% | 0.00% | – |
| Q4 2017 | $88,000 | – | 7,863 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Decheng Capital Management III (Cayman), LLC | 4,708,288 | $42,233,000 | 12.94% |
| Lynx1 Capital Management LP | 1,484,693 | $13,318,000 | 12.36% |
| Omega Fund Management, LLC | 2,029,580 | $18,205,000 | 3.73% |
| TCG Crossover Management, LLC | 1,034,222 | $9,277,000 | 3.72% |
| Frazier Life Sciences Management, L.P. | 4,185,757 | $37,546,000 | 3.20% |
| Paradigm Biocapital Advisors LP | 336,229 | $3,016,000 | 0.80% |
| Orbimed Advisors | 4,081,592 | $36,612,000 | 0.59% |
| BVF INC/IL | 1,589,495 | $14,258,000 | 0.57% |
| Kingsbury Capital Investment Advisors LLC | 29,153 | $262,000 | 0.29% |
| Avidity Partners Management LP | 1,207,000 | $10,827,000 | 0.22% |